Melanoma is a deadly form of skin cancer that has been increasing in the U.S. for the past 30 years. Nearly 100,000 new cases of melanoma are diagnosed every year, and 20 Americans die every day from it, according to the American Academy of Dermatology. Now, researchers have developed a fast-acting skin patch that efficiently delivers medication to attack melanoma cells. The device, tested in mice and human skin samples, is an advance toward developing a vaccine to treat melanoma and has widespread applications for other vaccines.
The researchers will present their findings today at the American Chemical Society (ACS) Fall 2019 National Meeting and Exposition. ACS, the world's largest scientific society, is holding the meeting here through Thursday. It features more than 9,500 presentations on a wide range of science topics.
"Our patch has a unique chemical coating and mode of action that allows it to be applied and removed from the skin in just a minute while still delivering a therapeutic dose of drugs," says Yanpu He, a graduate student who helped develop the device. "Our patches elicit a robust antibody response in living mice and show promise in eliciting a strong immune response in human skin."
Topical ointments can impart medications to the skin, but they can only penetrate a small distance through it. While syringes are an effective drug delivery mode, they can be painful. Syringes can also be inconvenient for patients, leading to noncompliance.
Microneedle patches, prepared with a layer-by-layer (LbL) coating method, are one easy, pain-free way to administer treatment. With the LbL process, researchers coat a surface with molecules of alternating positive and negative charge. For a robust drug film to form on the surface of the patch, every adjacent layer must be strongly attracted to each other and also to the microneedle.
"But this attraction makes the entire film very 'sticky,'" He notes. "Past methods, which have retained this 'sticky' nature, can take up to 90 minutes for a sufficient amount of drug to leave the patch and enter the skin."
Paula T. Hammond, Ph.D., along with her graduate students He, Celestine Hong and other colleagues at the Massachusetts Institute of Technology (MIT), devised a way around this problem. They designed a new pH-responsive polymer with two parts. "The first part contains amine groups that are positively charged at the pH at which we make the microneedles, but that become neutral at the pH of skin," He says.
"The second part contains carboxylic acid groups with no charge when the microneedles are made, but which become negatively charged when the patch is applied to the skin, so there is an overall change in charge from positive to negative." While sticky negative-positive-negative layers are still required for LbL film construction, the team's patch quickly switches to repelling negative-negative-negative layers when placed on skin. After the microneedles pierce the skin and implant the LbL drug film beneath the skin, the drug leaves the patch quickly.
Using chicken ovalbumin as a model antigen, the team vaccinated mice with their patches, and compared the results with intramuscular and subcutaneous injections. The microneedle treatment produced nine times the antibody level compared to intramuscular injections (e.g., used for flu shots) and 160 times the antibody level compared to subcutaneous injections (e.g., used for measles vaccines). They also saw efficient immune activation in surgical samples of human skin.
"Our patch technology could be used to deliver vaccines to combat different infectious diseases," Hammond says. "But we are excited by the possibility that the patch is another tool in the oncologists' arsenal against cancer, specifically melanoma."
To make a melanoma vaccine, the researchers developed an antigen that includes a marker frequently overexpressed by melanoma cells, as well as an adjuvant, which creates a generalized danger signal for the immune system and boosts its response. Then, they tested different LbL microneedle film arrangements of antigen and adjuvant in immune cells derived from mice.
From these experiments, the researchers identified the optimal LbL microneedle structure that appears to activate immune cells directly accessible in the skin. In living mice, these cells could, in turn, migrate to the lymphatic system and recruit other immune cells to attack the melanoma tumor. The researchers now plan to test the patches on melanoma tumors in mice.
"We are using low-cost chemistry and a simple fabrication scheme to transform vaccination," Hammond says. "Ultimately, we want to get a device approved and on the market."
A press conference on this topic will be held Monday, Aug. 26, at 2:30 p.m. Pacific time in the San Diego Convention Center. Reporters may check-in at the press center, Room 14B, Mezzanine Level, or watch live on Youtube http://bit.
The researchers acknowledge support and funding from the U.S. Department of Defense, Singapore-MIT Alliance for Research and Technology, the Koch Institute for Integrative Cancer Research at MIT and the Institute of Soldier Nanotechnologies at MIT.
The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive press releases from the American Chemical Society, contact firstname.lastname@example.org.
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
Synthetic charge-invertible polymer for rapid and complete implantation of layer-by-layer microneedle drug films for enhanced transdermal vaccination
The utility of layer-by-layer (LbL) coated microneedle (MN) skin patches for transdermal drug delivery has been proven a promising approach, with advantages over hypodermal injection due to painless and easy self-administration. However, the long epidermal application time required for drug implantation by existing LbL MN strategies (15 to 90 minutes) can lead to potential medication noncompliance. Here, we developed a MN platform to shorten the application time in MN therapies based on a synthetic pH-induced charge-invertible polymer poly(2-(diisopropylamino) ethyl methacrylate-b-methacrylic acid) (PDM), requiring only 1-minute skin insertion time to implant LbL films in vivo. Following MN-mediated delivery of 0.5 μg model antigen chicken ovalbumin (OVA) in the skin of mice, this system achieved sustained release over 3 days and led to an elevated immune response as demonstrated by significantly higher humoral immunity compared with OVA administration via conventional routes (subcutaneously and intramuscularly). Moreover, in an ex vivo experiment on human skin, we achieved efficient immune activation through MN-delivered LbL films, demonstrated by a rapid uptake of vaccine adjuvants by the antigen presenting cells. These features--rapid administration and the ability to elicit a robust immune response--can potentially enable a broad application of microneedle-based vaccination technologies.
Katie Cottingham, Ph.D. | EurekAlert!
Blocking the iron transport could stop tuberculosis
02.04.2020 | University of Zurich
Discovery of life in solid rock deep beneath sea may inspire new search for life on Mars
02.04.2020 | University of Tokyo
90 million-year-old forest soil provides unexpected evidence for exceptionally warm climate near the South Pole in the Cretaceous
An international team of researchers led by geoscientists from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) have now...
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply. When the iron transport into the bacteria is inhibited, the pathogen can no longer grow. This opens novel ways to develop targeted tuberculosis drugs.
One of the most devastating pathogens that lives inside human cells is Mycobacterium tuberculosis, the bacillus that causes tuberculosis. According to the...
An international team with the participation of Prof. Dr. Michael Kues from the Cluster of Excellence PhoenixD at Leibniz University Hannover has developed a new method for generating quantum-entangled photons in a spectral range of light that was previously inaccessible. The discovery can make the encryption of satellite-based communications much more secure in the future.
A 15-member research team from the UK, Germany and Japan has developed a new method for generating and detecting quantum-entangled photons at a wavelength of...
Together with their colleagues from the University of Würzburg, physicists from the group of Professor Alexander Szameit at the University of Rostock have devised a “funnel” for photons. Their discovery was recently published in the renowned journal Science and holds great promise for novel ultra-sensitive detectors as well as innovative applications in telecommunications and information processing.
The quantum-optical properties of light and its interaction with matter has fascinated the Rostock professor Alexander Szameit since College.
Researchers at the University of Zurich show that different stem cell populations are innervated in distinct ways. Innervation may therefore be crucial for proper tissue regeneration. They also demonstrate that cancer stem cells likewise establish contacts with nerves. Targeting tumour innervation could thus lead to new cancer therapies.
Stem cells can generate a variety of specific tissues and are increasingly used for clinical applications such as the replacement of bone or cartilage....
02.04.2020 | Event News
26.03.2020 | Event News
23.03.2020 | Event News
02.04.2020 | Information Technology
02.04.2020 | Health and Medicine
02.04.2020 | Materials Sciences